Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Celgene and IBM to Launch Drug Safety Program



The initiative – called IBM Watson for Patient Safety – will automatically collect, organize and analyze large amounts of data generated during, and after, drug development.

Share this!

November 7, 2016 | by Sarah Hand, M.Sc.

Participation in a clinical trial testing an experimental new drug is inherently risky, despite efforts made by the study sponsor to mitigate these risks. Even a drug which has a favorable safety profile throughout the clinical trials process may be associated with some serious adverse events after the drug has been launched on the market.

To address this issue, biotechnology company, Celgene has partnered with IT giant, IBM to launch a new drug safety program. The initiative – called IBM Watson for Patient Safety – will automatically collect, organize and analyze large amounts of data generated during, and after, drug development.

Watson is IBM’s technology platform that uses machine learning to analyze vast amounts of unstructured data. In this application, Watson will pull data from a multitude of sources, including electronic medical records and medical claims databases to support pharmaceutical and biotech companies throughout their drug development processes.

“For a long time, very big decisions around the use and disposition of drugs have been taken based on small datasets,” John Freeman, Celgene’s corporate vice president of global drug safety and risk management, told FierceBiotech. “This is an opportunity to not only streamline the way that information is handled within pharma companies and regulators, but also to enable much greater clarity of insight born of an ability to access large datasets.”

The benefit to pharma companies could be the ability to access and analyze side effects information from any given drug. Patients could also make use of the database by determining whether they are at risk of experiencing adverse events.

Watson will also be able to continuously update itself with every new piece of information it processes. This information could help pharmaceutical developers avoid the costs associated with failed drugs, thereby allowing them to focus their efforts on more promising therapeutics.

Keywords: Drug Safety, Adverse Event, Clinical Trial


Share this with your colleagues!

Insurance Coverage Under the Affordable Care Act Supports Clinical Trial Enrollment, Says Study

July 20, 2017 - Since the Patient Protection and Affordable Care Act (ACA) was passed in 2010, insurance approval for patients wishing to participate in oncology clinical trials has increased, according to a recent study published in the journal, Clinical Cancer Research.

Featured In: Clinical Trial News

FDA Approves Puma Biotechnology’s Extended Adjuvant Therapy for Breast

July 19, 2017 - Puma Biotechnology’s breast cancer drug Nerlynx (neratinib) has been approved by the US Food and Drug Administration (FDA).

Featured In: Biotech News

CAR-T Cell Therapy Shows Promise as Leukemia Treatment in Early Stage Clinical Trial

July 19, 2017 - About 70 percent of clinical trial participants with chronic lymphocytic leukemia experienced tumor shrinkage after being treated with CAR-T immunotherapy, according to researchers at Fred Hutchinson Cancer Research Center.

Featured In: Clinical Trial News


Manufacturing Control Strategies: What Pharmaceutical and Biotech Companies Need to Know


Outsourcing Pharmacovigilance: Pros and Cons and Lessons Learned

EDC and eSource: Combined for Better Data and Faster Insights

Using Model Reduction to Bridge the Quality Systems Pharmacology-Pharmacometrics Divide

How to Maximize Your Non-GLP Toxicology Studies: A Guide for Optimal Design and Methodology

Copyright © 2016-2017 Honeycomb Worldwide Inc.